{
    "clinical_study": {
        "@rank": "9917", 
        "arm_group": [
            {
                "arm_group_label": "Arm 1 - Treatment A, B, C, D", 
                "arm_group_type": "Other", 
                "description": "There are 4 treatment formulations:\nA: fasted, tablet formulation B: high-fat meal, tablet formulation C: low-fat meal, tablet formulation D: low-fat meal, capsule formulation\nIn Arm 1, the following order will be utilized:\nWeek 1, day 1: Treatment A Week 2, day 1: Treatment B Week 3, day 1: Treatment C Week 4, day 1: Treatment D"
            }, 
            {
                "arm_group_label": "Arm 2 - Treatment B, A, D, C", 
                "arm_group_type": "Other", 
                "description": "There are 4 treatment formulations:\nA: fasted, tablet formulation B: high-fat meal, tablet formulation C: low-fat meal, tablet formulation D: low-fat meal, capsule formulation\nIn Arm 1, the following order will be utilized:\nWeek 1, day 1: Treatment C Week 2, day 1: Treatment A Week 3, day 1: Treatment D Week 4, day 1: Treatment C"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this research study is to find out more information such as: to determine the\n      effects of high and low fat foods on the pharmacokinetics (PK) of oral KPT-330 tablets, to\n      compare PK of capsules and tablets, to assess the effects of KPT-330 on cellular morphology\n      and biomarker changes on sarcoma biopsy specimens (in patients who can safely undergo\n      biopsy)."
        }, 
        "brief_title": "A Phase I Trial to Assess the Effects of Food and Formulation on PK of KPT-330 in Patients With Sarcoma", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Sarcoma", 
        "condition_browse": {
            "mesh_term": "Sarcoma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Written informed consent in accordance with federal, local, and institutional\n             guidelines\n\n          2. Age \u226518 years\n\n          3. Patients must have histologically confirmed soft tissue or bone/cartilage sarcoma.\n             Patients with sarcoma of small round blue cell tumor types are allowed.\n             Gastrointestinal stromal tumors (GIST) are excluded.\n\n          4. Patients must have received at least one prior anticancer regimen for metastatic\n             disease unless there is no other therapy available and evidence of progressive\n             disease on study entry. Patients with stable disease will be included if there has\n             been failure to respond to another drug(s) within the previous 3 months\n\n          5. Eastern Cooperative Oncology Group Performance status of 0-1\n\n          6. Adequate hematopoietic function:\n\n               -  total white blood cell (WBC) count \u22652000/mm3\n\n               -  absolute neutrophil count (ANC) \u22651000/mm3\n\n               -  platelet count \u2265100,000/mm3\n\n          7. Adequate hepatic function:\n\n               -  bilirubin <1.5 \u00d7 the upper limit of normal (ULN)\n\n               -  alanine aminotransferase (ALT) <2 \u00d7 ULN\n\n          8. Adequate renal function: estimated creatinine clearance of \u2265 30 mL/min calculated\n             using the formula of Cockroft and Gault: (140-Age) \u2022 Mass (kg)/(72 \u2022 creatinine\n             mg/dL); multiply by 0.85 if female\n\n          9. Female patients of child-bearing potential must agree to use dual methods of\n             contraception and have a negative serum pregnancy test at screening, and male\n             patients must use an effective barrier method of contraception if sexually active\n             with a female of child-bearing potential. Acceptable methods of contraception are\n             condoms with contraceptive foam, oral, implantable or injectable contraceptives,\n             contraceptive patch, intrauterine device, diaphragm with spermicidal gel, or a sexual\n             partner who is surgically sterilized or post-menopausal. For both male and female\n             patients, effective methods of contraception must be used throughout the study and\n             for three months following the last dose\n\n        Exclusion Criteria:\n\n          1. Patients who are pregnant or lactating\n\n          2. Patients with known liver metastases\n\n          3. Radiation, chemotherapy, immunotherapy, any other systemic anticancer therapy or\n             participation in an investigational anti-cancer study \u2264 3 weeks prior to initiation\n             of therapy\n\n          4. Major surgery within four weeks before initiation of therapy\n\n          5. Unstable cardiovascular function:\n\n               -  symptomatic ischemia, or\n\n               -  uncontrolled clinically significant conduction abnormalities (e.g.: ventricular\n                  tachycardia on antiarrhythmics are excluded and 1st degree AV block or\n                  asymptomatic LAFB/RBBB will not be excluded) or\n\n               -  congestive heart failure (CHF) of NYHA Class \u22653, or\n\n               -  myocardial infarction (MI) within 3 months of initiation of therapy\n\n          6. Active, uncontrolled infection within one week prior to first dose\n\n          7. Known to be HIV seropositive\n\n          8. Known active hepatitis A, B, or C infection; or known to be positive for HCV RNA or\n             HBsAg (HBV surface antigen)\n\n          9. Patients with known brain metastasis\n\n         10. Patients with any gastrointestinal dysfunctions that could interfere with the\n             interpretation of the food effect data\n\n         11. Patients with known intolerance to low or high fat meals\n\n         12. In the opinion of the investigator, patients who are significantly below their ideal\n             body weight\n\n         13. Serious psychiatric or medical conditions that could interfere with treatment\n\n         14. Concurrent therapy with approved or investigational anticancer therapeutic including\n             topical therapies"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01896505", 
            "org_study_id": "KCP-330-003"
        }, 
        "intervention": {
            "arm_group_label": [
                "Arm 1 - Treatment A, B, C, D", 
                "Arm 2 - Treatment B, A, D, C"
            ], 
            "intervention_name": "KPT-330-003", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "bone", 
            "soft-tissue", 
            "sarcoma", 
            "KPT-330", 
            "food", 
            "effects"
        ], 
        "lastchanged_date": "September 11, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10065"
                    }, 
                    "name": "Memorial Sloan Kettering Cancer Centre"
                }, 
                "investigator": {
                    "last_name": "Gary Schwartz, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M5T 2M9"
                    }, 
                    "name": "Princess Margaret Hospital"
                }, 
                "investigator": {
                    "last_name": "Malcolm J Moore, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "An Open Label Phase IB Trial to Evaluate the Effects of Food and Formulation on Pharmacokinetics of the Oral Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Soft-Tissue or Bone Sarcoma", 
        "other_outcome": {
            "measure": "Biomarker changes on sarcoma biopsy specimens (in patients who can safely undergo biopsy).", 
            "safety_issue": "No", 
            "time_frame": "Baseline and Week 3 or 4 of Cycle 1"
        }, 
        "overall_contact": {
            "email": "mkauffman@karyopharm.com", 
            "last_name": "Michael Kauffman, MD PhD", 
            "phone": "+1 508-975-4822"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Canada: Health Canada"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Area under the plasma concentration versus time curve (AUC) of KPT-330", 
                "safety_issue": "Yes", 
                "time_frame": "At baseline (time 0) and on Day 1 of weeks 1 - 4 in Cycle 1 at the following timepoints:15 min, 30 min, 1, 1.5, 2, 3, 4, 5, 6, 8, 10,18 and 24 hours post dose"
            }, 
            {
                "measure": "Peak Plasma Concentration (Cmax) of KPT-330", 
                "safety_issue": "Yes", 
                "time_frame": "At baseline (time 0) and on Day 1 of weeks 1 - 4 in Cycle 1 at the following timepoints:15 min, 30 min, 1, 1.5, 2, 3, 4, 5, 6, 8, 10,18 and 24 hours post dose"
            }, 
            {
                "measure": "Comparison of AUC and Cmax of KPT-330 between: Treatment A vs B; Treatment C vs D; Treatment A vs C", 
                "safety_issue": "Yes", 
                "time_frame": "At baseline (time 0) and on Day 1 of weeks 1 - 4 in Cycle 1 at the following timepoints:15 min, 30 min, 1, 1.5, 2, 3, 4, 5, 6, 8, 10,18 and 24 hours post dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01896505"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Tumor response in sarcoma patients (RECISTv1.1 criteria)", 
                "safety_issue": "Yes", 
                "time_frame": "CT scans will be done at 8 weeks post dose and every 2 months while on study drug; and 30 days after the last dose in the study."
            }, 
            {
                "measure": "Change in laboratory parameters (serum chemistry, hematology and urinalysis)", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline and Day 1 of weeks 1 -4 in Cycle 1"
            }, 
            {
                "measure": "Change in ECG parameters", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline and Day 1 of each week (weeks 1-4) in Cycle 1"
            }, 
            {
                "measure": "Change in Vital sign parameters (Systolic pressure, diastolic pressure and heart rate)", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline and on Day 1 of each week (weeks 1 - 4) of Cycle 1"
            }, 
            {
                "measure": "Number and percentages of patients involved per CTCAE Category and CTCAE Term", 
                "safety_issue": "Yes", 
                "time_frame": "After first dose of drug until final study visit"
            }, 
            {
                "measure": "Highest relation of an AE to study drug", 
                "safety_issue": "Yes", 
                "time_frame": "After first dose until final visit"
            }, 
            {
                "measure": "Maximum AE severity", 
                "safety_issue": "Yes", 
                "time_frame": "After first dose of study drug until the final study visit"
            }
        ], 
        "source": "NPM Pharma Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "NPM Pharma Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}